Spiro-cyclic amine derivatives as S1P modulators

Patent metadata

Field	Value
Publication number	US-11427598-B2
Application number	US-202017007359-A
Country	US
Kind code	B2
Filing date	Aug 31, 2020
Priority date	Jul 9, 2010
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; —W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor(s) is(are) involved.

First claim

The invention claimed is:

1. A method of treating a disease or condition in a patient, wherein the disease or condition is selected from a cognitive disorder, Alzheimer's disease, vascular dementia, Niemann-Pick disease and a cognitive deficit, comprising administering to said patient a compound of formula:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof, or an N-oxide of any of the foregoing, wherein:
R1 is selected from the group consisting of:
cyano,
(2-4C)alkenyl, (2-4C)alkynyl, and (1-4C)alkyl, each optionally substituted with CN or one or more fluoro atoms,
(3-6C)cycloalkyl, (4-6C)cycloalkenyl and a (8-10C)bicyclic group, each optionally substituted with halogen or (1-4C)alkyl,
phenyl, biphenyl, and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, cyano, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-6C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino and (3-6C)cycloalkyl optionally substituted with phenyl which may be substituted with (1-4C)alkyl or halogen,
phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl and monocyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms,
monocyclic heterocycle optionally independently substituted with halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (3-6C)cycloalkyl, or phenyl optionally substituted with (1-4C)alkyl or halogen,
and
bicyclic heterocycle optionally substituted with halogen or (1-4C)alkyl optionally substituted with one or more fluoro atoms;

R2 is H or independently selected from one or more substituents selected from halogen, (1-4C)alkoxy and (1-4C)alkyl optionally substituted with one or more fluoro atoms; and
R3 is (1-4C)alkylene-R4 wherein the alkylene group may be substituted with one or more halogen atoms or with (CH 2 ) 2 to form a cyclopropyl moiety, or R3 is (3-6C)cycloalkylene-R4, —CH 2 -(3-6C)cycloalkylene-R4, (3-6C)cycloalkylene-CH 2 —R4 or —CO—CH 2 —R4, wherein R4 is —OH, —PO 3 H 2 , —OPO 3 H 2 , —COOH,
—COO(1-4C)alkyl or tetrazol-5-yl;

R5 is H or independently selected from one or more halogens; and
A represents a morpholine ring structure.

2. The method of claim 1 , wherein the cognitive deficit is selected from age-related cognitive decline and cognitive deficits in schizophrenia, obsessive-compulsive behavior, major depression, autism, multiple sclerosis, and pain.

3. The method of claim 1 , wherein the disease or condition is Niemann-Pick disease.

4. The method of claim 1 , wherein R1 is phenyl, biphenyl, or naphthyl, each optionally substituted with one or more substituents independently selected from halogen, cyano, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-6C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino and (3-6C)cycloalkyl optionally substituted with phenyl which may be substituted with (1-4C)alkyl or halogen.

5. The method of claim 1 , wherein R1 is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyl, cyclopropyl, and trifluoromethyl.

6. The method of claim 1 , wherein R2 is H.

7. The method of claim 1 , wherein R3 is (1-4C)alkylene-R4.

8. The method of claim 1 , wherein R3 is —(CH 2 ) 2 —COOH.

9. The method of claim 1 , wherein R4 is —COOH.

10. The method of claim 1 , wherein R5 is H.

Assignees

• Abbvie Deutschland

Inventors

• Stoit Axel
• Iwema Bakker Wouter I
• Coolen Hein K A C
• Van Dongen Maria J P
• Leflemme Nicolas J -L D
• Hobson Adrian

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K31/44

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title

• A61K31/443

  containing a five-membered ring with oxygen as a ring hetero atom · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D401/00

  Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom · CPC title